Spore-ing change: Rua Bioscience psilocybin study targets meth addiction

Spore-ing change: Rua Bioscience psilocybin study targets meth addiction
Gisborne-based pharmaceutical company Rua Bioscience is hoping mushrooms can help cure meth addiction. (Image: Supplied)
Gregor Thompson
Rua Bioscience is exploring psilocybin-containing mushrooms’ potential in treating methamphetamine addiction.The clinical study, dubbed Tū Wairua (standing with strength and spiritual connectedness), intends to combine historic Māori practices with modern science to tackle meth addiction.The New Zealand Exchange-listed (NZX) and the Gisborne-based medical cannabis company announced Phase I of the new trial on Tuesday.“Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessio...

More Markets

Sanford profit surges 224% as debt falls and aquaculture lifts earnings
Markets

Sanford profit surges 224% as debt falls and aquaculture lifts earnings

Better cash flow and lower debt helped drive seafood company Sanford’s net profit up by 223.8% to $63.7 million in the September year.Revenue was steady at $584.1m, and Sanford’s earnings before interest and tax came to $102.1m, up 88%.Managing director David Mair said it was an...

Serko swells in India, GetThere adds $8.8m revenue
Markets

Serko swells in India, GetThere adds $8.8m revenue

CEO says result is strongest ever as shares soar more than 8% in early trading.

Fletcher Residential worth $850m ‘on a good day’
Infrastructure

Fletcher Residential worth $850m ‘on a good day’

Shareholders have been clear no asset sales should be on the cheap.

Investors cream $214m from Fonterra Mainland sale
Primary Sector

Investors cream $214m from Fonterra Mainland sale

From “dismal” returns to a windfall and rocketing unit price. But what's next?